Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Quest Diagnostics Inc (DGX) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Quest Diagnostics Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1022079.
Total stock buying since 2015: $0.
Total stock sales since 2015: $452,903,674.
Total stock option exercises since 2015: $246,435,132.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 81,932 | $14,020,288 | 16,361 | $1,638,694 |
| 2024 | 0 | $0 | 137,855 | $21,480,666 | 119,555 | $10,882,491 |
| 2023 | 0 | $0 | 14,476 | $2,036,165 | 0 | $0 |
| 2022 | 0 | $0 | 495,105 | $69,749,779 | 476,765 | $42,554,328 |
| 2021 | 0 | $0 | 298,670 | $42,131,402 | 282,571 | $25,517,382 |
| 2020 | 0 | $0 | 972,125 | $112,334,987 | 954,164 | $64,519,249 |
| 2019 | 0 | $0 | 507,917 | $49,976,740 | 483,192 | $26,860,850 |
| 2018 | 0 | $0 | 668,422 | $71,110,395 | 592,295 | $34,511,327 |
| 2017 | 0 | $0 | 466,701 | $47,753,057 | 447,736 | $25,006,000 |
| 2016 | 0 | $0 | 245,446 | $19,181,053 | 226,734 | $13,333,851 |
| 2015 | 0 | $0 | 43,495 | $3,129,142 | 32,000 | $1,610,960 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 14,017 | $2,518,856 | 8,092 | $816,756 |
| 2025-07 | 0 | $0 | 10,479 | $1,759,930 | 8,269 | $821,938 |
| 2025-05 | 0 | $0 | 1,748 | $306,799 | 0 | $0 |
| 2025-04 | 0 | $0 | 41,746 | $7,047,439 | 0 | $0 |
| 2025-03 | 0 | $0 | 10,013 | $1,724,388 | 0 | $0 |
| 2025-02 | 0 | $0 | 3,929 | $662,876 | 0 | $0 |
| 2024-11 | 0 | $0 | 87,004 | $13,987,053 | 87,004 | $7,764,268 |
| 2024-10 | 0 | $0 | 1,775 | $278,525 | 0 | $0 |
| 2024-08 | 0 | $0 | 34,541 | $5,349,515 | 32,551 | $3,118,223 |
| 2024-07 | 0 | $0 | 420 | $60,093 | 0 | $0 |
| 2024-04 | 0 | $0 | 1,760 | $246,400 | 0 | $0 |
| 2024-02 | 0 | $0 | 12,355 | $1,559,080 | 0 | $0 |
| 2023-03 | 0 | $0 | 11,371 | $1,597,057 | 0 | $0 |
| 2023-02 | 0 | $0 | 3,105 | $439,108 | 0 | $0 |
| 2022-12 | 0 | $0 | 2,025 | $308,812 | 2,025 | $116,573 |
| 2022-11 | 0 | $0 | 42,765 | $6,368,015 | 42,765 | $3,654,151 |
| 2022-10 | 0 | $0 | 15,497 | $2,247,065 | 15,497 | $839,054 |
| 2022-09 | 0 | $0 | 2,000 | $250,040 | 2,000 | $122,450 |
| 2022-08 | 0 | $0 | 2,000 | $272,080 | 2,000 | $117,476 |
| 2022-07 | 0 | $0 | 2,000 | $266,940 | 2,000 | $114,936 |
| 2022-05 | 0 | $0 | 410,478 | $57,600,072 | 410,478 | $37,589,688 |
| 2022-03 | 0 | $0 | 13,260 | $1,792,883 | 0 | $0 |
| 2022-02 | 0 | $0 | 5,080 | $643,872 | 0 | $0 |
| 2021-11 | 0 | $0 | 37,565 | $5,847,630 | 37,565 | $3,598,539 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-21 | Plewman Patrick (SVP for Diagnostic Services) | Sale | 1,975 | 185.00 | 365,375 |
| 2025-08-19 | Plewman Patrick (SVP for Diagnostic Services) | Sale | 4,532 | 183.00 | 829,356 |
| 2025-08-19 | Plewman Patrick (SVP for Diagnostic Services) | Option Ex | 4,532 | 112.17 | 508,354 |
| 2025-08-15 | Plewman Patrick (SVP for Diagnostic Services) | Sale | 1,975 | 180.00 | 355,500 |
| 2025-08-06 | Plewman Patrick (SVP for Diagnostic Services) | Sale | 5,535 | 175.00 | 968,625 |
| 2025-08-06 | Plewman Patrick (SVP for Diagnostic Services) | Option Ex | 3,560 | 86.63 | 308,402 |
| 2025-07-31 | Kuppusamy Karthik (SVP, Clinical Solutions) | Sale | 2,210 | 170.00 | 375,700 |
| 2025-07-30 | Kuppusamy Karthik (SVP, Clinical Solutions) | Sale | 8,269 | 167.40 | 1,384,230 |
| 2025-07-30 | Kuppusamy Karthik (SVP, Clinical Solutions) | Option Ex | 8,269 | 99.40 | 821,938 |
| 2025-05-13 | Delaney Mark E (SVP & Chief Commercial Officer) | Sale | 874 | 175.31 | 153,220 |
| 2025-05-12 | Delaney Mark E (SVP & Chief Commercial Officer) | Sale | 874 | 175.72 | 153,579 |
| 2025-04-02 | Kuppusamy Karthik (SVP, Clinical Solutions) | Sale | 2,555 | 170.00 | 434,350 |
| 2025-04-02 | Davis J. E. (CEO and President) | Sale | 39,191 | 168.74 | 6,613,089 |
| 2025-03-17 | Prevoznik Michael E (SVP & General Counsel) | Sale | 4,643 | 170.00 | 789,310 |
| 2025-03-05 | Doherty Catherine T. (EVP, Regional Businesses) | Sale | 5,370 | 174.13 | 935,078 |
| 2025-02-27 | Doherty Catherine T. (EVP, Regional Businesses) | Sale | 824 | 172.61 | 142,230 |
| 2025-02-27 | Prevoznik Michael E (SVP & General Counsel) | Sale | 528 | 172.61 | 91,138 |
| 2025-02-20 | Prevoznik Michael E (SVP & General Counsel) | Sale | 604 | 170.99 | 103,277 |
| 2025-02-19 | Plewman Patrick (SVP for Diagnostic Services) | Sale | 320 | 169.71 | 54,307 |
| 2025-02-05 | Delaney Mark E (SVP & Chief Commercial Officer) | Sale | 403 | 164.30 | 66,214 |
| 2025-02-05 | Gregg Vicky B (Director) | Sale | 1,250 | 164.57 | 205,710 |
| 2024-11-29 | Prevoznik Michael E (SVP & General Counsel) | Sale | 35,146 | 162.70 | 5,718,359 |
| 2024-11-29 | Prevoznik Michael E (SVP & General Counsel) | Option Ex | 35,146 | 86.63 | 3,044,697 |
| 2024-11-27 | Doherty Catherine T. (EVP, Regional Businesses) | Sale | 33,103 | 162.64 | 5,383,838 |
| 2024-11-27 | Doherty Catherine T. (EVP, Regional Businesses) | Option Ex | 33,103 | 103.57 | 3,428,477 |
| 2024-11-06 | Deppe Michael J (SVP, Corp. Controller & CAO) | Sale | 18,755 | 153.82 | 2,884,856 |
| 2024-11-06 | Deppe Michael J (SVP, Corp. Controller & CAO) | Option Ex | 18,755 | 68.84 | 1,291,094 |
| 2024-10-28 | Kuppusamy Karthik (SVP, Clinical Solutions) | Sale | 1,775 | 156.92 | 278,525 |
| 2024-08-29 | Prevoznik Michael E (SVP & General Counsel) | Sale | 32,551 | 154.97 | 5,044,526 |
| 2024-08-29 | Prevoznik Michael E (SVP & General Counsel) | Option Ex | 32,551 | 95.80 | 3,118,223 |
| 2024-08-28 | Kuppusamy Karthik (SVP, Clinical Solutions) | Sale | 1,990 | 153.26 | 304,989 |
| 2024-07-24 | Delaney Mark E (SVP & Chief Commercial Officer) | Sale | 420 | 143.08 | 60,093 |
| 2024-04-29 | Kuppusamy Karthik (SVP, Clinical Solutions) | Sale | 1,760 | 140.00 | 246,400 |
| 2024-02-29 | Doherty Catherine T. (EVP, Regional Businesses) | Sale | 1,187 | 125.88 | 149,419 |
| 2024-02-29 | Prevoznik Michael E (SVP & General Counsel) | Sale | 5,611 | 125.88 | 706,312 |
| 2024-02-28 | Doherty Catherine T. (EVP, Regional Businesses) | Sale | 5,557 | 126.57 | 703,349 |
| 2023-03-07 | Doherty Catherine T. (SVP, Regional Businesses) | Sale | 5,307 | 140.55 | 745,898 |
| 2023-03-07 | Prevoznik Michael E (SVP & General Counsel) | Sale | 4,754 | 140.55 | 668,174 |
| 2023-03-03 | Doherty Catherine T. (SVP, Regional Businesses) | Sale | 717 | 140.63 | 100,831 |
| 2023-03-02 | Prevoznik Michael E (SVP & General Counsel) | Sale | 593 | 138.54 | 82,154 |
| 2023-02-24 | Doherty Catherine T. (SVP, Regional Businesses) | Sale | 1,690 | 141.42 | 238,999 |
| 2023-02-24 | Prevoznik Michael E (SVP & General Counsel) | Sale | 1,415 | 141.42 | 200,109 |
| 2022-12-01 | Ring Timothy M | Sale | 2,025 | 152.50 | 308,812 |
| 2022-12-01 | Ring Timothy M | Option Ex | 2,025 | 57.57 | 116,573 |
| 2022-11-28 | Doherty Catherine T. (SVP, Regional Businesses) | Sale | 40,765 | 149.15 | 6,079,895 |
| 2022-11-28 | Doherty Catherine T. (SVP, Regional Businesses) | Option Ex | 40,765 | 86.63 | 3,531,471 |
| 2022-11-01 | Ring Timothy M | Sale | 2,000 | 144.06 | 288,120 |
| 2022-11-01 | Ring Timothy M | Option Ex | 2,000 | 61.34 | 122,680 |
| 2022-10-26 | Deppe Michael J (VP, Corp. Controller & CAO) | Sale | 15,497 | 145.00 | 2,247,065 |
| 2022-10-26 | Deppe Michael J (VP, Corp. Controller & CAO) | Option Ex | 15,497 | 54.14 | 839,054 |
| 2022-09-01 | Ring Timothy M | Sale | 2,000 | 125.02 | 250,040 |
| 2022-09-01 | Ring Timothy M | Option Ex | 2,000 | 61.23 | 122,450 |
| 2022-08-01 | Ring Timothy M | Sale | 2,000 | 136.04 | 272,080 |
| 2022-08-01 | Ring Timothy M | Option Ex | 2,000 | 58.74 | 117,476 |
| 2022-07-01 | Ring Timothy M | Sale | 2,000 | 133.47 | 266,940 |
| 2022-07-01 | Ring Timothy M | Option Ex | 2,000 | 57.47 | 114,936 |
| 2022-05-24 | Rusckowski Stephen H (Chairman, CEO and President) | Sale | 282,408 | 140.12 | 39,571,291 |
| 2022-05-24 | Rusckowski Stephen H (Chairman, CEO and President) | Option Ex | 282,408 | 95.10 | 26,857,000 |
| 2022-05-23 | Rusckowski Stephen H (Chairman, CEO and President) | Sale | 77,466 | 141.30 | 10,945,790 |
| 2022-05-23 | Rusckowski Stephen H (Chairman, CEO and President) | Option Ex | 77,466 | 95.10 | 7,367,016 |
| 2022-05-17 | Prevoznik Michael E (SVP & General Counsel) | Sale | 50,604 | 139.97 | 7,082,991 |
| 2022-05-17 | Prevoznik Michael E (SVP & General Counsel) | Option Ex | 50,604 | 66.51 | 3,365,672 |
| 2022-03-08 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 7,032 | 135.21 | 950,796 |
| 2022-03-08 | Prevoznik Michael E (SVP & General Counsel) | Sale | 6,228 | 135.21 | 842,087 |
| 2022-02-28 | Prevoznik Michael E (SVP & General Counsel) | Sale | 661 | 130.00 | 85,930 |
| 2022-02-24 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 2,750 | 126.26 | 347,215 |
| 2022-02-24 | Prevoznik Michael E (SVP & General Counsel) | Sale | 1,669 | 126.26 | 210,727 |
| 2021-11-29 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 37,565 | 155.67 | 5,847,630 |
| 2021-11-29 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Option Ex | 37,565 | 95.80 | 3,598,539 |
| 2021-07-29 | Rusckowski Stephen H (Chairman, CEO and President) | Sale | 9,493 | 140.90 | 1,337,601 |
| 2021-07-29 | Rusckowski Stephen H (Chairman, CEO and President) | Option Ex | 9,493 | 95.80 | 909,381 |
| 2021-07-28 | Rusckowski Stephen H (Chairman, CEO and President) | Sale | 139,751 | 140.14 | 19,584,844 |
| 2021-07-28 | Rusckowski Stephen H (Chairman, CEO and President) | Option Ex | 139,751 | 95.80 | 13,387,447 |
| 2021-07-27 | Rusckowski Stephen H (Chairman, CEO and President) | Sale | 32,788 | 140.01 | 4,590,549 |
| 2021-07-27 | Rusckowski Stephen H (Chairman, CEO and President) | Option Ex | 32,788 | 95.80 | 3,140,926 |
| 2021-07-27 | Wilensky Gail R | Sale | 12,222 | 139.30 | 1,702,475 |
| 2021-07-27 | Wilensky Gail R | Option Ex | 12,222 | 59.40 | 725,925 |
| 2021-07-26 | Rusckowski Stephen H (Chairman, CEO and President) | Sale | 5,813 | 140.03 | 813,994 |
| 2021-07-26 | Rusckowski Stephen H (Chairman, CEO and President) | Option Ex | 5,813 | 95.80 | 556,856 |
| 2021-05-07 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 8,536 | 139.96 | 1,194,724 |
| 2021-05-05 | Prevoznik Michael E (SVP & General Counsel) | Sale | 44,939 | 137.00 | 6,156,643 |
| 2021-05-05 | Prevoznik Michael E (SVP & General Counsel) | Option Ex | 44,939 | 71.17 | 3,198,308 |
| 2021-03-10 | Prevoznik Michael E (SVP & General Counsel) | Sale | 5,574 | 120.47 | 671,499 |
| 2021-02-25 | Prevoznik Michael E (SVP & General Counsel) | Sale | 801 | 115.49 | 92,507 |
| 2021-02-24 | Prevoznik Michael E (SVP & General Counsel) | Sale | 1,188 | 116.95 | 138,936 |
| 2020-12-24 | Guinan Mark (Executive Vice President & CFO) | Sale | 81,756 | 120.62 | 9,861,245 |
| 2020-12-24 | Guinan Mark (Executive Vice President & CFO) | Option Ex | 81,756 | 66.51 | 5,437,591 |
| 2020-11-24 | Wilensky Gail R | Sale | 6,111 | 126.02 | 770,120 |
| 2020-11-24 | Wilensky Gail R | Option Ex | 6,111 | 57.66 | 352,390 |
| 2020-10-21 | Deppe Michael J (VP, Corp. Controller & CAO) | Sale | 10,450 | 125.00 | 1,306,250 |
| 2020-10-21 | Deppe Michael J (VP, Corp. Controller & CAO) | Option Ex | 10,450 | 57.21 | 597,875 |
| 2020-10-16 | Rusckowski Stephen H (Chairman, CEO and President) | Sale | 291,997 | 120.00 | 35,039,640 |
| 2020-10-16 | Rusckowski Stephen H (Chairman, CEO and President) | Option Ex | 291,997 | 66.51 | 19,420,720 |
| 2020-10-14 | Prevoznik Michael E (SVP & General Counsel) | Sale | 35,591 | 119.00 | 4,235,329 |
| 2020-10-14 | Prevoznik Michael E (SVP & General Counsel) | Option Ex | 35,591 | 52.16 | 1,856,604 |
| 2020-09-02 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 58,392 | 110.85 | 6,472,578 |
| 2020-09-02 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Option Ex | 58,392 | 66.51 | 3,883,651 |
| 2020-06-08 | Guinan Mark (Executive Vice President & CFO) | Sale | 72,596 | 117.69 | 8,543,678 |
| 2020-06-08 | Guinan Mark (Executive Vice President & CFO) | Option Ex | 72,596 | 71.17 | 5,166,657 |
| 2020-06-08 | Ring Timothy M | Sale | 11,730 | 116.60 | 1,367,718 |
| 2020-06-08 | Ring Timothy M | Option Ex | 11,730 | 59.61 | 699,272 |
| 2020-04-27 | Eglinton Manner Carrie (SVP, Advanced Diagnostics) | Sale | 5,000 | 111.02 | 555,075 |
| 2020-04-27 | Rusckowski Stephen H (Chairman, CEO and President) | Sale | 11,717 | 112.01 | 1,312,432 |
| 2020-04-27 | Rusckowski Stephen H (Chairman, CEO and President) | Option Ex | 11,717 | 71.17 | 833,898 |
| 2020-03-16 | Davis J. E. (EVP, General Diagnostics) | Sale | 3,513 | 87.75 | 308,251 |
| 2020-03-11 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 2,501 | 104.25 | 260,729 |
| 2020-03-11 | Prevoznik Michael E (SVP & General Counsel) | Sale | 2,175 | 104.25 | 226,743 |
| 2020-03-10 | Rusckowski Stephen H (Chairman, CEO and President) | Sale | 100 | 112.19 | 11,219 |
| 2020-03-10 | Rusckowski Stephen H (Chairman, CEO and President) | Option Ex | 100 | 71.17 | 7,117 |
| 2020-03-06 | Rusckowski Stephen H (Chairman, CEO and President) | Sale | 230,178 | 114.36 | 26,324,076 |
| 2020-03-06 | Rusckowski Stephen H (Chairman, CEO and President) | Option Ex | 230,178 | 71.17 | 16,381,768 |
| 2020-02-27 | Davis J. E. (EVP, General Diagnostics) | Sale | 1,100 | 109.02 | 119,922 |
| 2020-02-27 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 789 | 109.02 | 86,016 |
| 2020-02-27 | Prevoznik Michael E (SVP & General Counsel) | Sale | 690 | 109.02 | 75,223 |
| 2020-02-26 | Davis J. E. (EVP, General Diagnostics) | Sale | 510 | 111.09 | 56,655 |
| 2020-02-26 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 368 | 111.09 | 40,881 |
| 2020-02-26 | Prevoznik Michael E (SVP & General Counsel) | Sale | 321 | 111.09 | 35,659 |
| 2020-02-25 | Davis J. E. (EVP, General Diagnostics) | Sale | 598 | 112.73 | 67,412 |
| 2020-02-25 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 405 | 112.73 | 45,655 |
| 2020-01-02 | Davis J. E. (EVP, General Diagnostics) | Sale | 143,537 | 105.98 | 15,212,481 |
| 2020-01-02 | Davis J. E. (EVP, General Diagnostics) | Option Ex | 143,546 | 68.84 | 9,881,706 |
| 2019-11-27 | Prevoznik Michael E (SVP & General Counsel) | Sale | 44,556 | 107.50 | 4,789,814 |
| 2019-11-27 | Prevoznik Michael E (SVP & General Counsel) | Option Ex | 44,556 | 54.14 | 2,412,395 |
| 2019-09-17 | Deppe Michael J (VP, Corp. Controller & CAO) | Sale | 5,000 | 106.00 | 530,000 |
| 2019-09-17 | Deppe Michael J (VP, Corp. Controller & CAO) | Option Ex | 5,000 | 55.65 | 278,250 |
| 2019-06-13 | Guinan Mark (Executive Vice President & CFO) | Sale | 73,005 | 100.00 | 7,300,500 |
| 2019-06-13 | Guinan Mark (Executive Vice President & CFO) | Option Ex | 73,005 | 52.16 | 3,808,305 |
| 2019-06-13 | Rusckowski Stephen H (Chairman, President and CEO) | Sale | 244,565 | 100.00 | 24,456,500 |
| 2019-06-13 | Rusckowski Stephen H (Chairman, President and CEO) | Option Ex | 244,565 | 52.16 | 12,757,733 |
| 2019-04-24 | Davis J. E. (EVP, General Diagnostics) | Sale | 47,574 | 95.00 | 4,519,530 |
| 2019-04-24 | Davis J. E. (EVP, General Diagnostics) | Option Ex | 47,574 | 60.67 | 2,886,552 |
| 2019-04-08 | Davis J. E. (EVP, General Diagnostics) | Sale | 8,000 | 90.42 | 723,392 |
| 2019-04-04 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 66,382 | 90.59 | 6,013,744 |
| 2019-04-04 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Option Ex | 60,492 | 71.17 | 4,305,215 |
| 2019-03-04 | Cunningham Everett (SVP, Commercial) | Sale | 3,892 | 86.81 | 337,864 |
| 2019-03-04 | Prevoznik Michael E (SVP & General Counsel) | Sale | 3,373 | 86.81 | 292,810 |
| 2019-02-27 | Cunningham Everett (SVP, Commercial) | Sale | 1,144 | 86.51 | 98,967 |
| 2019-02-27 | Prevoznik Michael E (SVP & General Counsel) | Sale | 1,048 | 86.51 | 90,662 |
| 2019-02-26 | Cunningham Everett (SVP, Commercial) | Sale | 352 | 87.06 | 30,645 |
| 2019-02-26 | Prevoznik Michael E (SVP & General Counsel) | Sale | 364 | 87.06 | 31,689 |
| 2019-02-25 | Cunningham Everett (SVP, Commercial) | Sale | 326 | 88.23 | 28,762 |
| 2019-02-25 | Prevoznik Michael E (SVP & General Counsel) | Sale | 336 | 88.23 | 29,645 |
| 2019-02-22 | Wilensky Gail R | Sale | 8,000 | 87.78 | 702,216 |
| 2019-02-22 | Wilensky Gail R | Option Ex | 8,000 | 51.55 | 412,400 |
| 2018-07-10 | Cunningham Everett (SVP, Commercial) | Sale | 40,328 | 112.00 | 4,516,736 |
| 2018-07-10 | Cunningham Everett (SVP, Commercial) | Option Ex | 40,328 | 71.17 | 2,870,143 |
| 2018-07-10 | Prevoznik Michael E (SVP & General Counsel) | Sale | 30,780 | 113.06 | 3,480,140 |
| 2018-07-10 | Prevoznik Michael E (SVP & General Counsel) | Option Ex | 30,780 | 57.60 | 1,773,081 |
| 2018-07-02 | Cunningham Everett (SVP, Commercial) | Sale | 68,069 | 109.86 | 7,478,264 |
| 2018-07-02 | Cunningham Everett (SVP, Commercial) | Option Ex | 60,222 | 59.34 | 3,573,453 |
| 2018-05-29 | Leiden Jeffrey M | Sale | 1,644 | 105.61 | 173,622 |
| 2018-05-25 | Guinan Mark (Executive Vice President & CFO) | Sale | 61,533 | 105.78 | 6,508,899 |
| 2018-05-25 | Guinan Mark (Executive Vice President & CFO) | Option Ex | 61,533 | 58.37 | 3,591,373 |
| 2018-05-25 | Rusckowski Stephen H (Chairman, President and CEO) | Sale | 168,490 | 107.00 | 18,028,430 |
| 2018-05-25 | Rusckowski Stephen H (Chairman, President and CEO) | Option Ex | 168,490 | 56.12 | 9,455,658 |
| 2018-03-08 | Cohen Jon R (SVP & Group Exec. Diag. Sol.) | Sale | 83,669 | 104.47 | 8,741,318 |
| 2018-03-08 | Cohen Jon R (SVP & Group Exec. Diag. Sol.) | Option Ex | 38,928 | 66.51 | 2,589,101 |
| 2018-03-05 | Davis J. E. (EVP, General Diagnostics) | Sale | 5,122 | 101.00 | 517,322 |
| 2018-03-05 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 5,556 | 101.00 | 561,156 |
| 2018-03-05 | Prevoznik Michael E (SVP & General Counsel) | Sale | 4,128 | 101.00 | 416,928 |
| 2018-02-28 | Davis J. E. (EVP, General Diagnostics) | Sale | 648 | 104.99 | 68,033 |
| 2018-02-28 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 572 | 104.99 | 60,054 |
| 2018-02-28 | Prevoznik Michael E (SVP & General Counsel) | Sale | 496 | 104.99 | 52,075 |
| 2018-02-27 | Davis J. E. (EVP, General Diagnostics) | Sale | 1,150 | 104.10 | 119,715 |
| 2018-02-27 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 1,248 | 104.10 | 129,916 |
| 2018-02-27 | Prevoznik Michael E (SVP & General Counsel) | Sale | 927 | 104.10 | 96,500 |
| 2018-02-26 | Davis J. E. (EVP, General Diagnostics) | Sale | 494 | 102.74 | 50,753 |
| 2018-02-26 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 397 | 102.74 | 40,787 |
| 2018-02-26 | Klug Robert A (VP, Corporate Controller) | Sale | 1,157 | 103.66 | 119,932 |
| 2018-01-29 | Rusckowski Stephen H (Chairman, President and CEO) | Sale | 106,840 | 107.00 | 11,431,880 |
| 2018-01-29 | Rusckowski Stephen H (Chairman, President and CEO) | Option Ex | 106,840 | 58.17 | 6,215,417 |
| 2018-01-24 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 21,294 | 104.00 | 2,214,576 |
| 2018-01-24 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Option Ex | 21,294 | 52.16 | 1,110,801 |
| 2018-01-02 | Davis J. E. (EVP, General Diagnostics) | Sale | 63,880 | 98.67 | 6,303,359 |
| 2018-01-02 | Davis J. E. (EVP, General Diagnostics) | Option Ex | 63,880 | 52.16 | 3,332,300 |
| 2017-09-12 | Rusckowski Stephen H (Chairman, President and CEO) | Sale | 5,302 | 108.12 | 573,236 |
| 2017-09-12 | Rusckowski Stephen H (Chairman, President and CEO) | Option Ex | 5,302 | 58.17 | 308,443 |
| 2017-09-11 | Stanzione Daniel | Sale | 40,900 | 108.07 | 4,419,940 |
| 2017-09-11 | Stanzione Daniel | Option Ex | 40,900 | 57.51 | 2,352,077 |
| 2017-09-11 | Rusckowski Stephen H (Chairman, President and CEO) | Sale | 53,933 | 108.16 | 5,833,609 |
| 2017-09-11 | Rusckowski Stephen H (Chairman, President and CEO) | Option Ex | 53,933 | 58.17 | 3,137,552 |
| 2017-09-05 | Stanzione Daniel | Sale | 3,803 | 108.01 | 410,762 |
| 2017-09-05 | Stanzione Daniel | Option Ex | 3,803 | 56.75 | 215,835 |
| 2017-09-05 | Rusckowski Stephen H (Chairman, President and CEO) | Sale | 2,525 | 108.03 | 272,768 |
| 2017-09-05 | Rusckowski Stephen H (Chairman, President and CEO) | Option Ex | 2,525 | 58.17 | 146,891 |
| 2017-08-04 | Leiden Jeffrey M | Sale | 296 | 106.66 | 31,571 |
| 2017-07-27 | Leiden Jeffrey M | Sale | 1,304 | 108.73 | 141,782 |
| 2017-06-19 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 59,762 | 107.84 | 6,444,853 |
| 2017-06-19 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Option Ex | 59,762 | 57.02 | 3,407,928 |
| 2017-06-19 | Cohen Jon R (SVP & Group Exec. Diag. Sol.) | Sale | 106,900 | 107.83 | 11,527,347 |
| 2017-06-19 | Cohen Jon R (SVP & Group Exec. Diag. Sol.) | Option Ex | 106,900 | 55.30 | 5,911,249 |
| 2017-04-24 | Britell Jenne K | Sale | 6,111 | 104.03 | 635,727 |
| 2017-04-24 | Britell Jenne K | Option Ex | 6,111 | 57.67 | 352,421 |
| 2017-04-20 | Prevoznik Michael E (SVP & General Counsel) | Sale | 29,513 | 100.00 | 2,951,300 |
| 2017-04-20 | Prevoznik Michael E (SVP & General Counsel) | Option Ex | 29,513 | 56.23 | 1,659,663 |
| 2017-03-16 | Prevoznik Michael E (SVP & General Counsel) | Sale | 13,987 | 100.00 | 1,398,700 |
| 2017-03-16 | Prevoznik Michael E (SVP & General Counsel) | Option Ex | 13,987 | 55.65 | 778,376 |
| 2017-03-03 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 6,028 | 98.29 | 592,492 |
| 2017-03-03 | Prevoznik Michael E (SVP & General Counsel) | Sale | 4,478 | 98.29 | 440,142 |
| 2017-03-02 | Doherty Catherine T. (SVP, Group Exec. Clin. Fran.) | Sale | 1,134 | 98.25 | 111,415 |
| 2017-03-01 | Prevoznik Michael E (SVP & General Counsel) | Sale | 470 | 97.77 | 45,951 |
| 2017-02-27 | Prevoznik Michael E (SVP & General Counsel) | Sale | 440 | 97.39 | 42,851 |
| 2017-02-22 | Ziegler John B | Sale | 2,000 | 95.51 | 191,016 |
| 2017-02-15 | Doherty Catherine T. (SVP, Clin. Franchise Solutions) | Sale | 1,615 | 94.65 | 152,858 |
| 2017-02-13 | Prevoznik Michael E (SVP & General Counsel) | Sale | 1,200 | 93.76 | 112,512 |
| 2017-02-02 | Prevoznik Michael E (SVP & General Counsel) | Sale | 45,000 | 92.39 | 4,157,505 |
| 2017-02-02 | Prevoznik Michael E (SVP & General Counsel) | Option Ex | 45,000 | 53.42 | 2,404,125 |
| 2017-01-30 | Doherty Catherine T. (SVP, Clin. Franchise Solutions) | Sale | 80,000 | 90.81 | 7,264,720 |
| 2017-01-30 | Doherty Catherine T. (SVP, Clin. Franchise Solutions) | Option Ex | 80,000 | 54.14 | 4,331,440 |
| 2016-11-15 | Pfeiffer Gary M | Sale | 42,643 | 85.09 | 3,628,492 |
| 2016-11-15 | Pfeiffer Gary M | Option Ex | 34,333 | 56.75 | 1,948,500 |
| 2016-08-19 | Britell Jenne K | Sale | 4,000 | 84.76 | 339,052 |
| 2016-08-19 | Britell Jenne K | Option Ex | 4,000 | 55.76 | 223,040 |
| 2016-08-10 | Britell Jenne K | Sale | 4,000 | 85.20 | 340,808 |
| 2016-08-10 | Britell Jenne K | Option Ex | 4,000 | 55.76 | 223,040 |
| 2016-08-03 | Leiden Jeffrey M | Sale | 6,345 | 85.63 | 543,296 |
| 2016-08-03 | Leiden Jeffrey M | Option Ex | 6,641 | 69.88 | 464,079 |
| 2016-07-25 | Ziegler John B | Sale | 1,000 | 84.36 | 84,359 |
| 2016-05-27 | Doherty Catherine T. (SVP, Clin. Franchise Solutions) | Sale | 47,334 | 77.27 | 3,657,308 |
| 2016-05-27 | Doherty Catherine T. (SVP, Clin. Franchise Solutions) | Option Ex | 47,334 | 56.23 | 2,661,827 |
| 2016-05-09 | Cunningham Everett (SVP, Commercial) | Sale | 56,312 | 76.24 | 4,293,395 |
| 2016-05-09 | Cunningham Everett (SVP, Commercial) | Option Ex | 56,312 | 63.65 | 3,583,977 |
| 2016-05-06 | Cunningham Everett (SVP, Commercial) | Sale | 50,447 | 76.00 | 3,833,972 |
| 2016-05-06 | Cunningham Everett (SVP, Commercial) | Option Ex | 50,447 | 59.82 | 3,017,638 |
| 2016-04-25 | Doherty Catherine T. (SVP, Clin. Franchise Solutions) | Sale | 29,550 | 74.43 | 2,199,406 |
| 2016-04-25 | Doherty Catherine T. (SVP, Clin. Franchise Solutions) | Option Ex | 23,667 | 51.20 | 1,211,750 |
| 2016-03-01 | Prevoznik Michael E (SVP & General Counsel) | Sale | 3,815 | 68.41 | 260,965 |
| 2015-08-12 | Baldwin John C Md | Sale | 2,266 | 72.00 | 163,152 |
| 2015-08-06 | Ziegler John B | Sale | 2,200 | 74.35 | 163,570 |
| 2015-03-03 | Prevoznik Michael E (SVP & General Counsel) | Sale | 3,261 | 71.16 | 232,042 |
| 2015-02-17 | Guinan Mark (Senior Vice President & CFO) | Sale | 280 | 71.74 | 20,086 |
| 2015-02-17 | Prevoznik Michael E (SVP & General Counsel) | Sale | 488 | 71.41 | 34,848 |
| 2015-02-11 | Stanzione Daniel | Sale | 8,000 | 70.97 | 567,752 |
| 2015-02-11 | Stanzione Daniel | Option Ex | 8,000 | 49.94 | 399,520 |
| 2015-02-04 | Pfeiffer Gary M | Sale | 8,000 | 72.43 | 579,464 |
| 2015-02-04 | Pfeiffer Gary M | Option Ex | 8,000 | 49.94 | 399,520 |
| 2015-02-04 | Wilensky Gail R | Sale | 8,000 | 72.34 | 578,688 |
| 2015-02-04 | Wilensky Gail R | Option Ex | 8,000 | 49.94 | 399,520 |
| 2015-02-03 | Ziegler John B | Sale | 8,000 | 71.88 | 575,040 |
| 2015-02-03 | Ziegler John B | Option Ex | 8,000 | 51.55 | 412,400 |
| 2015-02-02 | Bongiorno Thomas F (VP and Corporate Controller) | Sale | 3,000 | 71.50 | 214,500 |
Insider trading activities including stock purchases, stock sales, and option exercises of DGX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Quest Diagnostics Inc (symbol DGX, CIK number 1022079) see the Securities and Exchange Commission (SEC) website.